101
Table 24. Recommended Monitoring for Patients Taking Oral
Amiodarone
Adverse Effect Baseline Testing
Initial Follow-Up
Testing
Additional
Follow-Up Testing
Hypo- or
hyperthyroidism
TSH (T4 and T3 if
TSH abnormal)
3–6 mo Every 6 mo
Hepatotoxicity AST, ALT 3–6 mo Every 6 mo
QT interval
prolongation
ECG Annually —
Interstitial lung
disease
Chest x-ray:
Recommended
CT chest: not
recommended
Chest x-ray:
Unexplained cough
or dyspnea or other
signs/symptoms
suspicious for
interstitial lung
disease
CT chest: As
indicated to
follow-up ongoing
symptoms or chest
x-ray findings
Corneal
microdeposits
(epithelial
keratopathy)
Not recommended Development of
visual abnormalities
which may indicate
optic neuropathy
—
Dermatologic
(blue-grey skin
discoloration),
photosensitivity
Not recommended Physical examination
annually
Development of
skin discoloration,
severe sunburn
Neurological Not recommended Physical examination
annually
Development
of peripheral
neuropathy or
other neurological
abnormalities
